Keywords: shire, adhd, drug, impresses, phase, iii, trial

Shire's ADHD drug impresses in Phase III trial

Article | 27 November 2006

Print This

UK-based drugmaker Shire says that data from a Phase III trial of its drug SPD503 (guanfacine extended release), administered as ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in